How Do Intellectual Property Law and International Trade Agreements Affect Access to Antiretroviral Therapy?
Open Access
- 8 August 2006
- journal article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (8), e332
- https://doi.org/10.1371/journal.pmed.0030332
Abstract
Westerhaus and Castro argue that US-negotiated bilateral, regional, and multilateral trade agreements are hindering access to essential HIV medicines in poor countries.Keywords
This publication has 10 references indexed in Scilit:
- TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way From Seattle to DohaPublished by Taylor & Francis ,2017
- The health of nations: happy birthday WTOThe Lancet, 2006
- Adherence to Antiretroviral Therapy: Merging the Clinical and Social Course of AIDSPLoS Medicine, 2005
- Health Innovation Networks to Help Developing Countries Address Neglected DiseasesScience, 2005
- Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?2004
- How Do Patents And Economic Policies Affect Access To Essential Medicines In Developing Countries?Health Affairs, 2004
- No agreement reached in talks on access to cheap drugsThe Lancet, 2002
- Do Patents for Antiretroviral Drugs Constrain Access to AIDS Treatment in Africa?JAMA, 2001
- Community-based approaches to HIV treatment in resource-poor settingsThe Lancet, 2001
- Access to Essential Drugs in Poor CountriesA Lost Battle?JAMA, 1999